


CYP Inhibition Assay Analysis Service



- Receive mass spectrometry data within 3 days
- Increase your lab's productivity
- Retain your lab's assay methods

Achieve more results ... Faster

Drug developers increasingly require faster and more predictive compound screens to reduce time-to-market and potential drug-drug interactions (DDI). With the BIOCIUS RapidFire[®] MS System, *in vitro* ADME assays can be performed using a reliable tool, the mass spectrometer, at previously unachievable throughputs. CYP inhibition assays using FDA recommended drug probes and MS analysis can now be performed early in drug discovery, eliminating the need for compromises often associated with plate reader-based methods. The RapidFire System produces throughputs >10-fold higher than standard LC-MS techniques allowing full IC₅₀ curves to be determined in the time required for a single endpoint using other systems. The same assay methods used in Development can now be efficiently utilized in Discovery providing assay consistency throughout the drug development process.

The RapidFire CYP Inhibition Assay Analysis Service increases your lab's productivity while preserving your assay method integrity. Simply send BIOCIUS your quenched assay plates and we will do the analysis, returning MS-based data within 3 days. We can analyze CYP inhibition assays (competitive or time dependent) for a number of P450 isoforms. Laboratory personnel and equipment can then be more efficiently utilized for other experiments.

Flexible screening service

Development and production of assays for alternative isoforms or probe substrates is also available. These assays may be used for DDI screening and follow-up retesting, including IC₅₀ and K_i determinations. BIOCIUS provides a combination of services and instrumentation to clients in the pharmaceutical and biotechnology industries in support of their drug development efforts.

- Use FDA recommended drug assay probes for assay consistency
 - Development assays in Discovery
- Full IC₅₀ curve data- no need to compromise methodology
- Complements existing workflows
 - 96 or 384 well plates
 - Compatible with human liver microsomes
- More efficiently utilize your laboratory resources

Available CYP Assays


CYP1A2	(tacrine, melatonin)
CYP2B6	(bupropion)
CYP2C8	(amodiaquin, taxol)
CYP2C9	(tolbutamide, diclofenac)
CYP2C19	(S-mephenytoin, omeprazole)
CYP2D6	(dextromethorphan, bufuralol)
CYP2E1	(chlorzoxazone)
CYP3A4/5	(midazolam, testosterone, nifedipine, erythromycin)

Custom assay development available.

Service details

The RapidFire CYP Inhibition Assay Analysis Service integrates easily into your existing laboratory workflow. Laborious sample preparation is not required - simply send BIOCIUS quenched 96 or 384 well plates from the defined CYP assays containing labeled internal standard. Samples are analyzed using BIOCIUS's RapidFire microscale solid-phase extraction sample preparation system interfaced to a triple-quadrupole mass spectrometer. Assay data are delivered within 3 days in a format that is easy to interpret and analyze within existing laboratory workflows.

The RapidFire CYP Inhibition Assay Analysis Service quickly provides high quality mass spectrometry based CYP inhibition assay data using FDA recommended drug probes. BIOCIUS's experienced scientists have screened millions of wells for our clients in the pharmaceutical and biotechnology industries in support of their drug discovery efforts. RapidFire Contract Research Services enable researchers to more efficiently utilize lab resources, obtain more data faster and make more informed decisions without compromising assay integrity.



Correlation Data Between Traditional LC-MS and RapidFire: Data from 8 different enzyme/substrate pairs and 1 to 3 inhibitors for each pair conducted using traditional LC-MS at BD Biosciences and RapidFire technology at BIOCIUS. The dotted line represents a line of unity.

